Medline Inc. has completed its upsized initial public offering (IPO) of 248,439,654 shares of Class A common stock at $29.00 per share, with underwriters fully exercising their option to purchase an additional 32,405,172 shares. The IPO closed on December 18, 2025, and the company’s stock now trades on the Nasdaq Global Select Market under the ticker MDLN.
Current Share Price:
In its prospectus, Medline said the portion of IPO proceeds retained by the company will primarily be used to repay outstanding term loan facilities and for general corporate purposes, while a separate portion will be used to purchase or redeem equity interests from certain pre-IPO owners.
Based in Northfield, Illinois, Medline is a large healthcare products and supply chain solutions company operating across hospitals, ambulatory surgery centers, physician offices and post-acute care settings. The company reports in its prospectus that it is a major provider of medical-surgical (med-surg) products and supply chain solutions across acute and non-acute care settings, operating through two business segments: Medline Brand and Supply Chain Solutions.
Across these segments, Medline offers a broad portfolio of med-surg consumables and related products used in routine patient care. Its Medline Brand portfolio includes products such as wound care supplies, gloves and protective apparel, urological and incontinence care items, infection control products and surgical and procedural kits. The Supply Chain Solutions segment distributes third-party med-surg products and provides logistics and supply chain support services for healthcare providers.
Medline supports its operations through a large US distribution and transportation network that serves hospitals, ambulatory centers, physician practices and post-acute care facilities.
The company also reports that many customers engage with Medline through long-term Prime Vendor arrangements, in which it functions as a consolidated distributor and logistics partner for med-surg product purchasing and delivery.
Activity Across the Healthcare Supply and Medtech Landscape
In 2025, total medtech M&A deal value was estimated at about $92.8 billion, marking the highest level in more than a decade, even as overall transaction counts remained below long-term norms.
Alongside capital markets activity, strategic transactions have continued among large healthcare organizations. Late last year, Cardinal Health acquired Solaris Health, a urology-focused management services organization, in a deal valued at about $1.9 billion in cash.
Market outlook data has also pointed to steady growth in core medical supplies categories, including consumables used in surgical and procedural settings. One recent forecast estimated the global medical supplies market at roughly $146 billion in 2024, with projections of growth toward about $215 billion by 2034 amid rising healthcare spending and broader clinical demand.
Within med-surg consumables specifically, Amsino International announced an agreement with ampiezza, a Vizient-supported aggregation group founded by Ochsner Health that serves more than 90 health systems, providing members with contracted pricing access to its portfolio of pre-filled flush syringes effective December 1, 2025.
In Europe, policy developments have also continued across the healthcare and medical device ecosystem. The European Commission has proposed a package that includes a Biotech Act and revisions to medical device rules, with measures intended to streamline aspects of regulatory processes, strengthen resilience and coordination across the sector and maintain high standards of patient safety.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN